Results 11 to 20 of about 71,439 (210)

First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

The Oncologist, EarlyView., 2021
Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi, Alessandra Ferro, Fabiana Cecere, Daniela Scattolin, Alessandro Del Conte, Alessandro Follador, Sara Pilotto, Valentina Polo, Mariacarmela Santarpia, Rita Chiari, Alberto Pavan, Alessandro Dal Maso, Valentina Da Ros, Giada Targato, Sabrina Vari, Stefano Indraccolo, Fiorella Calabrese, Stefano Frega, Laura Bonanno, Pier Franco Conte, Valentina Guarneri, Giulia Pasello   +21 more
wiley   +1 more source

Quantitative determination of erlotinib in human serum using competitive enzyme-linked immunosorbent assay

Journal of Pharmaceutical Analysis, 2018
A selective and sensitive competitive enzyme-linked immunosorbent assay (ELISA) method was developed and validated for the quantification of erlotinib in 50 µL of samples of human serum.
Yuta Yamamoto, Tetsuya Saita, Yutaro Yamamoto, Masashi Shin   +3 more
doaj   +1 more source

Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer [PDF]

, 2016
Epidermal growth factor receptor (EGFR) inhibitors such as erlotinib are novel effective agents in the treatment of EGFR-driven lung cancer, but their clinical impact is often impaired by acquired drug resistance through the secondary T790M EGFR mutation.
Chater, E, De Bruin, E, Downward, J, Heynen, GJJE, Hu, Y, Li, H, Liu, Z, Pardo, OE, Roy, R, Seckl, MJS, Smit, EF, Stokes, W, Tang, H, Wang, Y   +13 more
core   +2 more sources

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer

ERJ Open Research, 2022
Introduction Previous studies have shown interference between epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing efficacy.
Rolof G.P. Gijtenbeek, Vincent van der Noort, Joachim G.J.V. Aerts, Jeske A. Staal-van den Brekel, Egbert F. Smit, Frans H. Krouwels, Frank A. Wilschut, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Joost D.J. Janssen, Martijn Goosens, Paul M. van den Berg, A. Joop de Langen, Jos A. Stigt, Ben E.E.M. van den Borne, Harry J.M. Groen, Wouter H. van Geffen, Anthonie J. van der Wekken   +18 more
doaj   +1 more source

NRF2 regulates HER1 signaling pathway to modulate the sensitivity of ovarian cancer cells to lapatinib and erlotinib [PDF]

, 2017
NF-E2-related factor 2 (NRF2) regulates the transcription of a battery of metabolic and cytoprotective genes. NRF2 and epidermal growth factor receptors (EGFRs/HERs) are regulators of cellular proliferation and determinants of cancer initiation and ...
Bown, James L., Deeni, Yusuf Y., Hamza Kankia, Ibrahim, Khalil, Hilal S., Langdon, Simon P., Moult, Peter R.   +5 more
core   +6 more sources

Transcriptomic changes underlying EGFR inhibitor resistance in human and mouse models of basal-like breast cancer

Scientific Reports, 2022
The goals of this study were to identify transcriptomic changes that arise in basal-like breast cancer cells during the development of resistance to epidermal growth factor receptor inhibitors (EGFRi) and to identify drugs that are cytotoxic once EGFRi ...
Narmeen S. Rashid, David C. Boyd, Amy L. Olex, Jacqueline M. Grible, Alex K. Duong, Mohammad A. Alzubi, Julia E. Altman, Tess J. Leftwich, Aaron D. Valentine, Nicole S. Hairr, Emily K. Zboril, Timothy M. Smith, Adam D. Pfefferle, Mikhail G. Dozmorov, J. Chuck Harrell   +14 more
doaj   +1 more source

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer [PDF]

, 2013
AIM: To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed dose-rate gemcitabine (FDR-Gem) in advanced pancreatic cancer.
Bria, E., Cognetti, F., Gamucci, T., Gelibter, A., Mansueto, G., Milella, M., Moscetti, L., Ruggeri, E. M., Sperduti, I., Vaccaro, V.   +9 more
core   +1 more source

Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: Two case reports [PDF]

, 2008
Background: With the current improvements in primary lung care, the long-term control of brain metastases becomes a clinical challenge. No established therapeutic approaches exist for cranial relapse after response to previous radiotherapy and systemic ...
Abrey LE, Barbara Poellinger, Ceresoli GR, Delattre Y, Horst Wagner, Hotta K, Joachim von Pawel, Khantia D, Lai CS, Namba Y, Regine WF, Rodrigus P, Thomas Duell, Zabel A   +13 more
core   +1 more source

The Role of ARL4C in Erlotinib Resistance: Activation of the Jak2/Stat 5/β-Catenin Signaling Pathway

Frontiers in Oncology, 2020
Cancer patients who initially benefit from Erlotinib, a drug targeting EGFR path, eventually develop resistance to the drug. The underlying mechanism is largely unknown.
Jinrong Liao, Zeng Chen, Zongyang Yu, Tao Huang, Dan Hu, Ying Su, Zhiyong He, Changyan Zou, Lurong Zhang, Xiandong Lin, Xiandong Lin   +10 more
doaj   +1 more source

Challenges of drug resistance in the management of pancreatic cancer [PDF]

, 2010
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor).
Akada, Allison, Almoguera, Andreetta, Arai, Arlt, Arteaga, Arumugam, Asano, Bachem, Baldwin, Banerjee, Bartsch, Bergers, Best, Bold, Bondar, Buck, Burris, Chakravarti, Chakravarti, Choi, Cunningham, Cunningham, Dancer, Dong, Duxbury, Duxbury, Duxbury, Duxbury, Engelman, Feldmann, Ferrero, Galmarini, Geyer, Giovannetti, Goan, Greer, Hagmann, Hahn, Henke, Hruban, Humeniuk, Ischenko, Ishikawa, Itoi, Jansen, Karapetis, Kindler, Kong, Koopman, Kulik, Lei, Lemoine, Liau, Liau, Longley, Mackey, Mackey, Mackey, Mahon, Mamaghani, Marechal, Marmor, Martin Clynes, Mata, Maxwell, Mendelsohn, Meropol, Miwa, Moertel, Molina-Arcas, Moore, Morgillo, Moriyama, Muerkoster, Muerkoster, Nakahira, Nakajima, Nakano, Naomi Walsh, Nishimura, Oguri, Okamoto, Okumura, Olive, O’Driscoll, Pao, Park, Park, Peters, Plunkett, Ray McDermott, Ritzel, Rizwan Sheikh, Robert O’Connor, Ruggeri, Safran, Saito, Sakamoto, Schuller, Sebastiani, Shah, Shi, Simon, Spratlin, Takao, Takebayashi, Treat, Tsukamoto, Tzeng, Vaishampayan, Van Cutsem, van der Wilt, Wang, Wang, Wang, Xiong, Yamasaki, Yokoi   +119 more
core   +1 more source